Key Takeaways WST expects Q2 revenues of $720M-$730M and EPS of $1.50-$1.55, with organic sales up 3%-4%. WST's Proprietary Products segment is set to grow 4.6%, led by GLP-1 demand and SmartDose platform gains. WST's Contract Manufacturing gains from GLP-1 injectors as CGM volume winds down and new projects ramp.West Pharmaceutical Services (WST) is scheduled to release second-quarter 2025 results on July 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of ...